1. Date of download: 6/25/2016 Copyright © The American College of Cardiology. All rights reserved. From: Implantation of a Drug-Eluting Stent With a Different Drug (Switch Strategy) in Patients With Drug- Eluting Stent Restenosis: Results From a Prospective Multicenter Study (RIBS III [Restenosis Intra-Stent: Balloon Angioplasty Versus Drug-Eluting Stent]) J Am Coll Cardiol Intv. 2012;5(7):728-737. doi:10.1016/j.jcin.2012.03.017 The RIBS III Study Flow Chart BA = balloon angioplasty; BMS = bare-metal stent(s); DES = drug-eluting stent(s); ISR = in-stent restenosis; Pts = patients. Figure Legend:

2. Date of download: 6/25/2016 Copyright © The American College of Cardiology. All rights reserved. From: Implantation of a Drug-Eluting Stent With a Different Drug (Switch Strategy) in Patients With Drug- Eluting Stent Restenosis: Results From a Prospective Multicenter Study (RIBS III [Restenosis Intra-Stent: Balloon Angioplasty Versus Drug-Eluting Stent]) J Am Coll Cardiol Intv. 2012;5(7):728-737. doi:10.1016/j.jcin.2012.03.017 Cumulative Frequency Distribution Curves of MLD Cumulative frequency distribution curves of minimal lumen diameters (MLD) before the procedure (Pre), after intervention (Post) and at late follow-up (FU). Different-drug-eluting-stent group (blue curves), other strategy (red curves) (p = 0.003 for difference of means in MLD at follow-up). Figure Legend:

3. Date of download: 6/25/2016 Copyright © The American College of Cardiology. All rights reserved. From: Implantation of a Drug-Eluting Stent With a Different Drug (Switch Strategy) in Patients With Drug- Eluting Stent Restenosis: Results From a Prospective Multicenter Study (RIBS III [Restenosis Intra-Stent: Balloon Angioplasty Versus Drug-Eluting Stent]) J Am Coll Cardiol Intv. 2012;5(7):728-737. doi:10.1016/j.jcin.2012.03.017 Kaplan-Meier Estimates of Event-Free Survival (A) Freedom from major adverse cardiac events (MACE) (cardiac death, myocardial infarction, and target lesion revascularization [TLR]). (B) Freedom from TLR. The number of patients at risk in each time interval is presented at the bottom. DES = drug-eluting stent(s). Figure Legend:

4. Date of download: 6/25/2016 Copyright © The American College of Cardiology. All rights reserved. From: Implantation of a Drug-Eluting Stent With a Different Drug (Switch Strategy) in Patients With Drug- Eluting Stent Restenosis: Results From a Prospective Multicenter Study (RIBS III [Restenosis Intra-Stent: Balloon Angioplasty Versus Drug-Eluting Stent]) J Am Coll Cardiol Intv. 2012;5(7):728-737. doi:10.1016/j.jcin.2012.03.017 Comparison of Main Clinical and Angiographic Outcome Measures Between Treatment Strategies Comparisons are presented as crude estimates, adjusted (Adj.) (logistic regression or Cox analysis), and propensity score adjusted. MAE = major adverse events; HR = hazard ratio; RR = relative risk; other abbreviations as in Figures 1 to 3. Figure Legend:

5. Date of download: 6/25/2016 Copyright © The American College of Cardiology. All rights reserved. From: Implantation of a Drug-Eluting Stent With a Different Drug (Switch Strategy) in Patients With Drug- Eluting Stent Restenosis: Results From a Prospective Multicenter Study (RIBS III [Restenosis Intra-Stent: Balloon Angioplasty Versus Drug-Eluting Stent]) J Am Coll Cardiol Intv. 2012;5(7):728-737. doi:10.1016/j.jcin.2012.03.017 Main Outcome Measures Compared Only Between the Different-DES and Same-DES Strategies Outcome measures are presented as crude estimates, adjusted with logistic regression or Cox analysis, and propensity adjusted. Abbreviations as in Figures 1 to 4. Figure Legend: